natgillin/translations-raw huggingface dataset:
The use according to claim 11, wherein the beta2-adrenoceptor agonist is provided as the enantiomerically pure or as the enantiomerically enriched R-enantiomer of the beta2-adrenoceptor agonist selected from the group consisting of Amiterol; Bamethan; Bitolterol; Butaxamine; Carbuterol; Cimaterol; Colterol; Clenbuterol; Clorprenaline; Colterol; Deterenol; Dioxethedrin; Etafedrine;Ethylnorepinephrine; Fenoterol; Indacaterol; Isoproterenol; Mabuterol; Meluadrine; Nardeterol; Norbudrine; Norepinephrine; Orciprenaline; Picumeterol; Pirbuterol; Quinprenaline; Reproterol; Salbutamol; Salmeterol; Soterenol; Sulfonterol; Terbutaline; Tulobuterol; Zinterol; a physiologically acceptable derivative thereof and a pharmaceutically acceptable salt thereof. 
Agonist beta2-adrenoceptora prema zahtjevu 1, naznačen time da je navedeni beta2- agonist adrenoceptora predviđen kao enantiomerno čist ili kao enantiomerno obogaćen R-enantiomer agonista beta2-adrenoceptora odabran iz skupine koja se sastoji od Amiterola; Bametana; Bitolterola; Butaksamina; Karbuterola; Cimaterola; Kolterola; Klenbuterola; Klorprenalina; Kolterola; Deterenola; Dioksetedrina; Etafedrina; Etilnorepinefrina; Fenoterola; Indakaterola; Izoproterenola; Mabuterola; Meluadrina; Nardeterola; Norbudrina; Norepinefrina; Orciprenalina; Pikumeterola; Pirbuterola; Kvinprenalina; Reproterola; Salbutamola; Salmeterola; Soterenola; Sulfonterola; Terbutalina; Tulobuterola; Zinterola; i njegova farmaceutski prihvatljiva sol.
The average weight of the tablets was 250 mg/tablet. 
Prosječna masa tableta bila je 250 mg/tableti.
each R5 is independently hydrogen, alkyl, haloalkyl, hydroxyalkyl,or alkoxyalkyl; and and R7 are each independently hydrogen or alkyl. 
Q*i Q* svaki od njih nezavisno vodik, alkil, halo, haloalkil, opcijski supstituirani monociklički cikloalkil, opcijski supstituirani = monociklički = cikloalkilalkil,
5,354,772, cerivastatin, as disclosed in U.S. Patent Nos. 
5,354,772, cerivastatin, kao što je navedeno u U.S. Patentima br.
The composition according to claim 1, wherein component (A) is 3difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl) amide and component (B2) is selected from the group consisting of difenoconazole, propiconazole, cyproconazole and epoxiconazole. 
Pripravak prema zahtjevu 1, naznačen time da sadrži kao komponentu (A) spoj 3-difluorometil-1-metil-1Hpirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-il)amid, a kao komponentu (B) fludioksonil.
at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of at least 1,000,000; and mg oxycodone hydrochloride; and wherein the composition comprises at least about 65% (by wt) polyethylene oxide. 
(1) najmanje jedan polietilen oksid koji ima, prema Teološkim mjerenjima, približnu molekularnu težinu od najmanje 1,000,000; te (2) 40 mg oksikodon hidroklorida; 1 pri čemu pripravak sadrži barem oko 65 % (težinski) polietilen oksida.
Furthermore, Grayson et al, have recently demonstrated efficacy of risperidone to attenuate the sub-chronic PCP-induced deficit in this paradigm. 
Nadalje, Grayson 1 sur., su u novije vrijeme pokazali učinkovitost risperidona na smanjivanje sub-kroničnog deficita potaknutog PCP u ovom obrascu.
at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of less than 1,000,000. The solid oral extended release pharmaceutical dosage form of item 78, wherein the composition comprises at least about 80 % (by wt) of polyethylene oxide. 
(1) najmanje jedan polietilen oksid koji ima, prema reološkim mjerenjima, približnu molekularnu težinu od najmanje 1,000,000; i (2) 60 mg ili 80 mg oksikodon hidroklorida; 1 pri čemu pripravak sadrži barem oko 60 % (težinski) polietilen oksida.
The composition according to the invention can also comprise binders, such as polyvinyl pyrrolidone, microcrystalline cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, low-substituted hydroxypropyl cellulose, hydroxypropylmethyl cellulose or other cellulose ethers, starch, pregelatinised starch, or polymethacrylate or mixtures of binders. 
Pripravak prema izuma također može sadržavati 1 vezujuća sredstva, kao što su polivinil pirolidon, mikrokristalna celuloza, hidroksietilna celuloza, hidroksipropilna celuloza, nisko supstituirana hidroksipropilna celuloza, hidroksipropilmetilna celuloza ili drugi celulozni eteri, škrob, preželatinizirani škrob, ili polimetakrilat ili smjese vezujućih sredstava.
The animal models described in the documents above may be used to evaluate the efficacy of antikine antibodies in treating the associated condition, disorder or disease and these models and methods of their use are incorporated by reference to the documents above. Besides the diseases highlighted above, numerous other conditions, disorders and diseases have been associated with the activity of one or more chemokines, these include but are not limited to: oncogenic diseases, inflammatory bowel diseases, atopic dermatitis, psoriasis, stroke, organ transplantation, COPD, glomerulonephritis, lupus nephritis, scleroderma, cirrhosis, Alzheimer's disease, CHF-ischemia, coronary restenosis, diabetic nephropathy/neuropathy/retinopathy, osteoarthritis, periodontitis, yeast and viral infections, and dysregulation of pregnancy. 
Monoklonsko protutijelo u skladu s patentnim zahtjevom 1, ili njegov fragment koji veže antigen za upotrebu pri liječenju bolesti, poremećaja ili stanja uzrokovanih jednim ili više CC kemokina, naznačeno time, da je navedena bolest, poremećaj ili stanje odabrano iz skupine koja se sastoji od reumatoidnog artritisa, multiple skleroze, fibrozne bolesti, ateroskleroze, astme, onkogenih bolesti, upalne bolesti crijeva, atopičnog dermatitisa, psorijaze, moždanog udara, transplantacije organa, COPD, glomerulonefritisa, lupus nefritisa, skleroderma, ciroze, Alzheimer-ove bolesti, CHF-ishemije, koronarne restenoze, dijabetičke nefropatije / neuropatije / retinopatije, osteoartritisa, periodontitisa, infekcija uzrokovanih kvascem 1 virusima, te deregulacija trudnoće.
The VH of RY9A2v5(IAW)01 antibody has the amino acid sequence shown by SEQ ID NO: 8, and VL has the amino acid sequence shown by SEQ ID NO: 61. 
(c) varijabilno područje jakog lanca koje se sastoji od aminokiselinske sekvence prikazane sa SEQ ID NO:15 1 varijabilno područje slabog lanca koje se sastoji od aminokiselinske sekvence prikazane sa SEQ ID NO:9;
The composition can be a liquid, beverage, or gel that also includes a viscosity modifier, such as collagen, gellan gum, carbohydrate gel-forming polymers, carob bean gum, locust bean gum, carrageenan, alginic acid, sodium alginate, potassium alginate, ammonium alginate, calcium alginate, agar, guar gum, xanthan gum, carboxymethyl cellulose, clear starch, pectin, gelatin, arrowroot, cornstarch, katakuri starch, potato starch, sago, tapioca, furcellaran, or sodium pyrophosphate. 
(b) modifikator viskoznosti, proizvoljno kada je navedeni modifikator viskoznosti kolagen, gelan guma, ugljikohidratni polimeri koji tvore gel, guma od zrna karnaube, guma od rogača, karagenan, alginska kiselina, natrijev alginat, kalijev alginat, amonijev alginat, kalcijev alginat, agar, guar guma, ksantan guma, karboksimetil celuloza, čisti škrob, pektin, želatina, indijska maranta, kukuruzni škrob, katakuri škrob, škrob od krumpira, sago, tapioka, furcelaran, ili natrijev pirofosfat, proizvoljno kada navedeni pripravak ima viskoznost između oko 1000 1 oko 10000 cP.
As noted herein above, a topical gel formulation according to the present invention further comprises an active pharmaceutical ingredient, namely the alpha adrenergic receptor agonist brimonidine or the pharmaceutically acceptable tartrate salt thereof, that is effective to prevent or treat a skin disorder. 
Kompozicija topičkog gela prema zahtjevu 1, pri čemu kompozicija gela dalje sadrži agonist alfa adrenergijskog receptora ili njegovu farmaceutski prihvatljivu sol.
Coating composition having a pigment volume concentration (PVC) of from 5 vol.-% up to the critical pigment volume concentration (CPVC), characterised in that it comprises 
HR P20171268 T1 PATENTNI ZAHTJEVI Smjesa za premazivanje s volumnom koncentracijom pigmenta (PVC) od 5 vol-% do kritične volumne koncentracije pigmenta (CPVC), naznačena time što sadrži
These caps may be misplaced if they are separate from the mouthpiece or main body of the inhaler thus defeating their purpose. 
Ovi zatvarači mogu se međusobno zamijeniti ako se odvoje od kljuna ili glavnog tijela inhalatora čime gube svoju svrhu.
A composition for use according to claim 1, comprising baclofen and acamprosate, or pharmaceutically acceptable salts or derivatives thereof, as the only active agents. 
Smjesa za uporabu prema zahtjevu 1, sadrži baklofen i akamprozat kao jedine djelatne tvari.
leukemia, lymphoma, non-Hodgkins disease, chronic and acute myeloid leukaemia, acute lymphoblastic leukemia, Hodgkins disease, multiple myeloma and T-cell lymphoma; 
leukemija, limfom, ne-Hodgkinova bolest, kronična i akutna mijeloična leukemija, akutna limfoblastična leukemija, Hodgkinova bolest, multipli mijelom i limfom T-stanica;
The method of claim 1, wherein the solid support comprises microparticles, or a patterned surface, or wells. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što čvrsti nosač uključuje mikročestice, ili površinu s uzorkom, ili jažice.
Process according to claim 1, characterized in that a gas flow is released from the top of the first reactor section and the top of the second reactor section and the combined gas flow of both reactor sections is sent to a medium-pressure scrubber or a high-pressure scrubber, wherein ammonia and carbon dioxide present in the combined gas flow are removed from the gas flow by absorption in a low-pressure carbamate stream. 
Postupak prema zahtjevu 1, naznačen time što se protok plina oslobađa od vrha prvaog reaktorskog dijela i od vrha drugog reaktorskog dijela, a kombinirani protok plina oba odjeljka reaktora šalje sredstvima za gašenje srednjeg tlaka ili sredstvima za gašenje visokog tlaka, pri čemu se amonijak i ugljični dioksid prisutni u kombiniranom protoku plina uklanjaju iz protoka plina apsorpcijom u struji karbamata niskog tlaka.
The composition according to claim 1, which further comprises at least one chelating agent selected from the group consisting of ethylenediaminetetraacetic acid (EDTA) and ethylene glycol tetraacetic acid (EGTA). 
Kompozicija za primjenu prema bilo kojem od patentnih zahtjeva 1 do 5, gdje kompozicija dalje sadrži najmanje jedan helatni agens odabran od etilen diamintetraoctene kiseline (EDTA) 1 etilen glikol tetraoctene kiseline (EGTA).
Crystalline methylthioninium chloride dihydrate as Form C, having the following characteristic peaks in a powder X-ray diffraction pattern using CuKa radiation: 
Kristalni metiltioninium klorid monohidrat u Obliku E, naznačen time, da ima slijedeće karakteristične maksimume u difraktogramu rendgenske difrakcije praha (koristeći CuKa kao izvor radijacije, na valnoj duljini od 1.54180 Å):
By pharmaceutically acceptable form it is understood, “inter alia”, having an pharmaceutically acceptable level of purity excluding usual pharmaceutical additives such as diluents and carriers, and including material considered non-toxic at levels of normal doses. 
Kao farmaceutski prihvatljiv oblik podrazumijeva se, između ostalog, da on ima farmaceutski prihvatljivu razinu čistoće bez uobičajenih farmaceutskih dodataka kao što su sredstva za razređivanje i nosači, uključivši materijal koji se smatra netoksičan na razinama normalnih doza.
The method of claim 9 wherein said sequencing comprises the use of a sequencing array. 
Postupak prema zahtjevu 1, naznačen time da navedeno sekvenciranje sadrži upotrebu sekvencirajućeg niza.
Such a pharmaceutically acceptable composition may have a pH of about 9.1 to about 9.8 at 25° C. 
Farmaceutski prihvatljiv tekući sastav iz zahtjeva 1, naznačeno time da spomenuti sastav ima pH vrijednost od 9,2 do 9,8 na 25*C.
wherein the amino acid residue of position 435 (EU numbering) in the amino acid sequence of the antibody Fc domain or antibody heavy-chain constant region is histidine in either one of the first polypeptide having an antigen-binding activity and the second polypeptide having an antigen-binding activity or no antigen-binding activity; and wherein the amino acid residue of position 435 (EU numbering) in the amino acid sequence of the antibody Fc domain or antibody heavy-chain constant region is arginine in the other polypeptide. The polypeptide multimer of any one of claims 37 to 41, wherein the first polypeptide having an antigen-binding activity and the second polypeptide having an antigen-binding activity comprise an amino acid sequence of an antibody heavy-chain variable region, and at least one amino acid residue has been modified in the amino acid sequences of FR1, CDR2, and FR3 of the heavy-chain variable region. 
Metoda iz patentnog zahtjeva 4, pri čemu čistoća prikupljenog polipeptidnog multimera je 95% ili više; i/ili ii) pri čemu prvi polipeptid koji ima antigen-vezujuću aktivnost i drugi polipeptid koji ima antigen-vezujuću aktivnost sadrže aminokiselinsku sekvencu varijabilne regije teškog lanca antitijela, posebno pri čemu je najmanje jedan aminokiselinski ostatak modificiran u aminokiselinske sekvence od FR1, CDR2, i FR3 varijabilne regije teškog lanca antitijela; i/ili iii) pri čemu polipeptidni multimer sadrži jedan ili dva treća polipeptida koji imaju antigen-vezujuću aktivnost, i korak (a) obuhvaća eksprimiranje DNK koja kodira treći polipeptid koji ima antigen-vezujuću aktivnost, posebno
solvent deasphalting the first residuum to generate a deasphalted oil and an asphaltenes fraction; 
deasfaltiranje otapalom prvog ostatka kako bi se dobilo deasfaltirano ulje i frakcija asfaltena;
A lifting apparatus capable of engaging with and disengaging from a water treatment device which is to be lifted, the lifting apparatus comprising: 
Uređaj za podizanje (4) koji se može priključiti i odvojiti od uređaja za obradu vode (3) koji treba podići, pri čemu uređaj za podizanje (4) sadržava:
The compound of claim 4, which is: or a pharmaceutically acceptable salt or stereoisomer thereof. 
Spoj sukladno zahtjevu 1, s formulom: (JA ili njegova farmaceutski prihvatljiva sol ili stereoizomer.
The compound for use in a method of treatment or the use of any one of claims 15 to 19, wherein the compound is for treating a condition mediated by Raf kinase, optionally wherein the Raf kinase is a mutant b-Raf kinase such as b-Raf(V600E). 
Spoj za uporabu u postupku liječenja prema bilo kojem zahtjevu od 8 do 12 ili uporaba prema bilo kojem zahtjevu od 8 do 12, naznačen(a) time, da je to spoj za liječenje stanja posredovanog Raf-kinazom, pri čemu je opcijski Raf-kinaza mutirala od b-Raf-kinaze, kao primjerice b-Raf(V600E).
A method for treating kidney injury, hypertension, heart failure, myocardial infarction, angina pectoris, cardiac hypertrophy, myocarditis, cardiovascular fibrosis, baroceptor dysfunction, arrhythmia, and primary aldosteronism, which method comprises administering a pharmaceutical preparation containing a compound according to claim 1, or a pharmaceutically acceptable salt or an isomer thereof, and one or more pharmaceutically acceptable carrier to a subject in need thereof. 
Spoj prema bilo kojem od zahtjeva 1-15, ili njegova farmaceutski prihvatljiva sol za uporabu u liječenju i/ili prevenciji ozljede bubrega i/ili kardiovaskularne bolesti uključujući hipertenziju, zatajenje srca, miokardijalni infarkt, anginu pectoris, srčanu hipertrofiju, miokarditis, kardiovaskularnu fibrozu, baroceptorsku disfunkciju, višak fluida 1 aritmiju, ili endokrine bolesti, uključujući primarni/sekundarni aldosteronizam, Addisonovu bolest, Cushingov sindrom i Bartterov sindrom.
is a group represented by any of the following formulas: 
X skupina koja je prikazana bilo kojom od slijedećih formula:
contacting a G protein-coupled receptor with an optionally labelled known ligand to the receptor in the presence or absence of a test compound, wherein said G protein coupled receptor comprises an amino acid sequence selected from the group consisting of: 
(a) stavljanje u kontakt G protein-kupiranog receptora sa po izboru označenim poznatim ligandom za receptor u prisutnosti ili odsutnosti test spoja, pri čemu navedeni G protein kupirani receptor obuhvaća aminokiselinsku sekvencu izabranu iz skupine koju čine:
thereby to produce a solid ligand-modified poly oxo-hydroxy metal ion material having the desired physico-chemical property. 
čime se proizvodi kruti materijal poli-okso-hidroksi-metalnih iona modificiran ligandima, koji ima željena fizikalno-kemijska svojstva.
A compound of Formula (I) or a therapeutically acceptable salt thereof, wherein R1, R2, and R3 are independently selected from the group consisting of hydrogen, alkenyl, alkoxy, alkoxycarbonyl alkyl, alkynyl, cyano, haloalkoxy, haloalkyl, halogen, hydroxy, hydroxyalkyl, nitro, NRARB, and (NRARB)carbonyl; 
Ra JAPA Ra D, ili njegova terapijski prihvatljiva sol, naznačena time, da Ri, R> i Rs su neovisno odabrani iz skupine koja se sastoji od vodika, alkenila, alkoksi, alkoksikarbonil alkila, alkinila, cijano, haloalkoksi, haloalkila, halogena, hidroksi, hidroksialkila, nitro, NRARsg i (NRaRs)karbonila;
The deficit is only observed in the retention phase of the task, suggesting a specific and relatively subtle cognitive impairment. 
Deficit je zamijećen jedino u retencijskoj fazi zadatka, sugerirajući specifično 1 relativno fino kognitivno oštećenje.
The formulation of any one of claims 1 to 4 wherein the macrocyclic lactone concentration is from about 0.1% to about 2% (w/v); the levamisole concentration is from about 15% to about 30% (w/v); and the surfactant concentration is from about 1% to about 10% (w/v). 
Formulacija prema bilo kojem od zahtjeva 1 do 4, naznačena time, da je koncentracija makrocikličkog laktona od oko 0,1 % do oko 2% (masa/volumen); koncentracija levamisola je od oko 15% do oko 30% (masa/volumen); i koncentracija tenzida je od oko 1% do oko 10% (masa/volumen).
A dispenser according to claim 10 comprising a third ring member being coaxially arranged about said longitudinal axis. 
Dispenzer sukladno zahtjevu 12 koji sadrži treći prstenasti dio (1502) koji je koaksijalno raspoređen oko navedene uzdužne osi (214).
Use according to any one of claims 1 to 3, characterized in that one or more additional other cytotoxic, chemotherapeutic or anti-cancer agents, or compounds or ionizing radiation that enhance the effects of such agents are administered. 
Uporaba prema bilo kojem od zahtjeva 1 do 3, naznačena time, da se primjenjuju jedan ili više dodatnih ostalih citotoksičnih, kemoterapeutskih 1li antikanceroznih sredstava, ili spojevi ili ionizacijska radijacija koji/koja pojačava/ju učinke takvih sredstava.
The extended release dosage form of any one of claims 1 to 28, wherein the density of the extended release matrix formulation is equal to or less than 1.20 g/cm3, preferably equal to or less than 1.19 g/cm3. 
Oblik za doziranje s produljenim otpuštanjem prema bilo kojem zahtjevu od 1 do 28, naznačen time da je gustoća formulacije matrice s produljenim otpuštanjem a jednaka ili niža od 1.20 g/em', poželjno jednaka ili niža od 1.19 g/cm'.
it has a higher galactosylation degree with at least a 5% higher amount of G2 structures on the total carbohydrate structures or on the carbohydrate structures at one particular glycosylation site of the antibody molecule of the antibody molecules in said antibody molecule composition than the same amount of antibody molecules of at least one antibody molecule composition of the same antibody molecule isolated from CHOdhfr− [ATCC No. 
- sadrži količinu fukoze na ukupnim ugljikohidratnim strukturama ili na ugljikohidratnim strukturama na nekom određenom mjestu glikoziliranja u molekuli protutijela kod navedenih molekula protutijela u navedenom pripravku s molekulom protutijela koja je najmanje 5% manja u usporedbi s istom količinom molekula protutijela u pripravku s najmanje jednom molekulom protutijela za istu molekula protutijela izoliranu iz ATCC No.
The present inventors have found that the use of organic solvents and humidity control during crystallization treatments lead to the formation of MTC pentahydrate Form A, which can be easier dried and simultaneously maintains MTC pentahydrate form A under stability conditions of MTC pentahydrate Form A. A first aspect of the invention is a process for the preparation of substantially pure methylthioninium chloride pentahydrate Form A, wherein methylthioninium chloride is suspended in an organic solvent with a water content corresponding to a water activity of at least 0.4 at 25° C., the suspension is kept at low temperature, and the solid is isolated and dried to remove the organic solvent and any excess water from the solid; 
Postupak proizvodnje bitno čistog metiltioninijklorid pentahidrata u Obliku A, naznačen time, da: a) o metiltioninijklorid se suspendira u organskom otapalu sa sadržajem vode koji odgovara vodenom aktivitetu od najmanje 0,4 na 25*C, a pritom se suspenzija drži na niskoj temperaturi, dok se krutina izolira i suši kako bi se odstranilo organsko otapalo i bilo koji višak vode iz krutine; b) metiltioninijklorid se otapa na povišenim temperaturama u organskom otapalu sa sadržajem vode koji odgovara vodenom aktivitetu od najmanje 0,4 na 25C, a pritom se otopina hladi, dok se nataložena krutina izolira i suši kako bi se odstranilo organsko otapalo i bilo koji višak vode iz krutine; ili
and two R10, or two R11, or two R12 on the same N can cyclize to form a 4-6 membered heterocyclic ring optionally substituted with C1-4 alkyl, C1-4 alkoxy, hydroxy, or oxo; 
te dva R10, ili dva R11, ili dva R12 na istom N mogu ciklirati kako bi tvorili 4-6-člani heterociklični prsten izborno supstituiran s C1-4 alkil, C1-4 alkoksi, hidroksi ili okso;
Topical compositions for use as claimed in claims 1-9 wherein the mucous membranes are the external mucous membranes of the mouth and oral cavity, nasal mucosa, ocular mucosa, auricular mucosa, male and female genital mucosa, anal and rectal mucosa. 
Topički pripravci za upotrebu kako su prijavljeni u patentnim zahtjevima 1 - 9, naznačeni time da membrane sluznice jesu vanjske membrane sluznice usta, oralne šupljine, nosne šupljine, okulama sluznica, sluzica uha, sluznica muških i ženskih genitalija te rektalna sluznica.
The circulating fluidized bed combustion system of claim 11, wherein the separation device comprises one or more pitch vanes that redirects a portion of the secondary combustion air within the sorbent feed path to the second air injection port. 
Cirkulacijski sustav kotla s izgaranjem u fluidiziranom sloju prema zahtjevu 11, naznačen time da uređaj za razdvajanje zraka/sorbenta (208) preusmjerava sekundarni zrak unutar putanje dovođenja sorbenta pod kutom od oko 120 stupnjeva do oko 170 stupnjeva.
cooling the solution resulting from step (iii) to a temperature of about 10° C.; adjusting the solution resulting from step (iii) to a protein concentration of about 5.7%, adjusting pH to a value of about 5.7 by addition of an aqueous solution of lactic acid, and adding NaCl to a concentration of about 1.9%; 
(111) hlađenje otopine dobivene u koraku (11) do temperature od 10%C; (iv) podešavanje otopine dobivene u koraku (iii) do koncentracije proteina od 5.7% 1 pH vrijednosti od 5.7 putem dodavanja vodene otopine mliječne kiseline i dodavanja NaC1 do koncentracije od 1.9%;
The alkyl esters are preferably monofunctional and can only be reacted with the polyfunctional resins, thus, all of the diluent contribute to produce a thermoset network. 
Alkil esteri imaju ponajprije jednu funkcionalnu skupinu i oni mogu reagirati samo s polifunkcionalnim smolama, stoga, dakle sva sredstva za razrjeđivanje doprinose stvaranju duromerne mreže.
said hybridoma cell line 3C12F was deposited on August 12,2010 at the American Type Culture Collection (ATCC) under the accession number PTA-11261, 
navedena hibridna stanična linija 3C12F pohranjena 12. kolovoza 2010. u American Type Culture Collection (ATCC) pod pristupnim brojem PTA-11261,